A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in participants with incurable non-small cell lung cancer identified to be Met diagnostic-positive. Participants will be randomized to receive either onartuzumab (MetMAb) or placebo in combination with erlotinib. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Checked against the public recordLast updated Nov 2, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Genentech, Inc.
- Interventions being studied
- Drug: Erlotinib; Drug: Onartuzumab (MetMab); Drug: Placebo
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Adult participants, greater than or equal to (\>/=) 18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Histologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumor * Met diagnostic-positive status tested by immunohistochemistry (IHC) * Results of endothelial growth factor receptor (EGFR)-activating mutation testing * Radiographic evidence of disease * Prior treatment with at least one platinum-based line of treatment (for stage IIIb/IV) and no more than one additional line of chemotherapy treatment; the last dose of chemotherapy must have been administered \>/= 21 days prior to Day 1 * availability of tissue sample for diagnostic testing is required Exclusion Criteria: * More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known EGFR-related toxicity resulting in dose modifications (EGFR inhibitors including but not limited to gefitinib, erlotinib and cetuximab) * Brain metastases or spinal cord compression not definitively treated with surgery and/or radiation, or previously treated central nervous system (CNS) metastases or spinal cord compression without evidence of stable disease for \>/= 14 days * History of another malignancy in the previous 3 years, unless cured by surgery alone and continuously disease free for at least 3 years; participants with prior history of non-invasive cancers are eligible * Inadequate hematological, biochemical or organ function * Significant history of cardiac disease * Serious active infection at time of randomization or other serious underlying medical conditions that would impair the ability of the participant to receive protocol treatment * Any inflammatory changes of the surface of the eye * Clinically significant gastro-intestinal disease, including uncontrolled inflammatory gastro-intestinal diseases * Pregnant or lactating women * Positive for human immunodefinciency (HIV) infection
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Study locationChandler, Arizona
- Study locationHayward, California
- Study locationModesto, California
- Study locationOakland, California
- Study locationOrange, California
- Study locationRoseville, California
- Study locationSacramento, California
- Study locationSacramento, California
- Study locationSan Diego, California
- Study locationSan Francisco, California
- Study locationSan Jose, California
- Study locationSanta Clara, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 2, 2016. Always confirm current availability with the study team.